A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma

Key Points

• The aim is to evaluate the safety and effectiveness of interleukin-15 combined with avelumab in treating relapsed or refractory T-cell lymphoma.
• Phase 1 clinical trial design
• Participants with relapsed or refractory T-cell lymphoma
• Combination therapy of interleukin-15 and avelumab
• Monitoring for safety and therapeutic response
• The combination therapy showed a manageable safety profile.
• Some participants exhibited objective responses to the treatment.
• The findings suggest a promising avenue for future immunotherapy strategies in T-cell lymphoma.